Monday, May 5, 2014

PLGA-PEG nanoparticles for treatment of leishmaniasis

PolySciTech (www.polyscitech.com) provides a wide array of biodegradable block PLGA-Peg type copolymers. Recently these types of polymers have been used for enhanced treatment of leishmaniasis by deliverying amphotericin B. Read more Kumar, Rishikesh, Ganesh Chandra Sahoo, Krishna Pandey, V. N. R. Das, and Pradeep Das. "Study the effects of PLGA-PEG encapsulated Amphotericin B nanoparticle drug delivery system against Leishmania donovani." Drug delivery 0 (2014): 1-6. http://informahealthcare.com/doi/abs/10.3109/10717544.2014.891271

“Abstract: Drug delivery systems are a promising technology to increase poor solubility and bioavailability of compounds. Therefore we have developed PLGA-PEG encapsulated amphotericin B nanoparticles (NPs) drug delivery technology to increase the solubility of amphotericin B and target the macrophage of infected tissues during visceral leishmaniasis. The structural characterization by transmission electron microscopy and dynamic light scattering revealed the nano-size of the particle (30–35 nanometers). Fourier transform infrared spectroscopy confirmed the PLGA-PEG encapsulation. The mean cytotoxic assay (0.0803 + 0.0253) of extracellular promastigote of PLGA-PEG encapsulated amphotericin B is significantly lower than that of amphotericin B (0.1134 + 0.0153) and inhibition of amastigotes in the splenic tissue was significantly more than with conventional amphotericin B (93.02 + 6.63 versus 74.42 +14.78). Amphotericin B encapsulated PLGA-PEG nanoparticles were found to be more effective than free amphotericin B in terms of therapeutic efficacy during in vitro and in vivo study. Keywords: Amastigotes, amphotericin B, electron microscope, kala azar, nanometer, PLGA-PEG, promastigote”
Post a Comment